FDA
Bimzelx Beats Skyrizi 49% to 38% on ACR50 in PsA Trial
BE BOLD's Phase 3 data put a 10-point ACR50 gap between Bimzelx and Skyrizi, the $17.56B drug AbbVie built its post-Humira franchise on.
FDA Desk
FDA enforcement, inspections, approvals.
Form 483 observations, Warning Letters, CRLs, approvals, advisory votes. What FDA inspectors actually flagged — and what it means for compliance.
8
Stories this week
3
Reporters
10
Active topics
All filings
102 filings
No filings match this filter in the first page.
About this desk
What we cover
Form 483 observations, Warning Letters, Complete Response Letters, consent decrees, import alerts, drug and device approvals, advisory committee votes, and inspectional findings from pharma and biotech facilities. We read the letter, match the observations to cGMP code sections, and explain what the inspector actually flagged.
Why it matters for compliance
A Form 483 is the most public signal FDA gives before a Warning Letter, and a Warning Letter is the last public signal before an import alert or consent decree. Reading them in sequence shows where the agency is focusing inspector attention this quarter — data integrity, cleaning validation, process control, or aseptic technique. Drug approval timelines, CRL reasons, and panel votes set the pace for every downstream regulatory decision.
Frequently asked
What is a Form 483? +
A Form 483 is the document FDA investigators hand to facility management at the end of an inspection, listing observed conditions that may violate the Food, Drug, and Cosmetic Act. Companies typically have 15 business days to respond in writing before the agency escalates.
How is a Warning Letter different from a Form 483? +
A 483 lists observations from a single inspection. A Warning Letter is issued later, at district-office level, and takes the position that specific violations require corrective action. Warning Letters are public; 483s become public only through FOIA or voluntary company disclosure.
Do you cover every FDA Warning Letter? +
Not every letter — only those affecting publicly traded or VC-backed companies, drug shortages, or where the observations point to industry-wide GMP trends. Full FDA letter archives are available through the agency website.
How quickly do you publish after an approval or CRL? +
Approvals and CRLs disclosed in 8-K filings or PDUFA-date press releases go up within 2–4 hours. Agency-issued Warning Letters typically appear on the FDA site Tuesday; we publish same-day analysis.